GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » Short Percentage of Float

Cynata Therapeutics (ASX:CYP) Short Percentage of Float


View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Cynata Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Cynata Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cynata Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's Short Percentage of Float falls into.


Cynata Therapeutics (ASX:CYP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » Short Percentage of Float
Comparable Companies
ASX:BIT ASX:SPL ASX:EZZ ASX:ADO ASX:LTP ASX:PTX ASX:ACW ASX:PAA ASX:ATH ASX:NOX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
51S:Germany
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Website
https://www.cynata.com
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines